Accessibility Tools

Emerging Treatments for ADHD

Emerging Treatments for ADHD

Emerging Treatments for ADHD

Emerging medications for ADHD are slowly coming to the market for physicians to use.  They tend to be more long‑acting and cover 12 to 16 hours.  Many times today with kids homework/sports a longer formulations is needed.  The agents below modulate norepinephrine amongst other hormones.  An agent that has been used for some time is Straterra which works similarly.

Beyond those, there is an agent that is about to have an FDA review. It scheduled in this fall, in November, I believe. The agent is viloxazine extended‑release formulation. It is medication that in addition to being norepinephrine uptake inhibitor, is also a serotonin 2C agonist, and serotonin 2B antagonist, so this is medication that modulates both norepinephrine and serotonin.

What may be an advantage? It remains to be proven, but you would wonder, in children who have comorbid anxiety, who have comorbid depression, or prominent emotional dysregulation in ADHD, might an agent like this be of help?

In addition to that, it's important to appreciate that serotonin itself has a significant role in ADHD. There have been studies both looking at peripheral metabolites of serotonin, as well as cerebrospinal fluid metabolites of serotonin. They have found association between these markers of serotonin transmission and irritability, hostility, aggression, impulsivity, and hyperactivity in ADHD.

Will presence of ability to modify serotonin in some way provide a different profile of ADHD treatment, relative to currently available agents?

Finally, there is an agent that is so‑called triple‑action modulator, a norepinephrine, dopamine, serotonin modulator that is. They have published data in phase 2B out in the market.

It seems that the focus is now looking at agents that are capable of modulating norepinephrine and dopamine akin to stimulants, but also may engage serotonin transmission, hopefully providing a wider spectrum of symptom relief.

Dr. Priti Kothari
Child, Adolescent & Adult Psychiatry
 priti kothari
Dr. Priti Kothari is a board certified child, adolescent and adult psychiatrist with fellowship training at John Hopkins Medical Center. Dr. Kothari completed her undergraduate studies at Princeton University with a major in Anthropology and a concentration in Women’s Studies. She then went on to perform research in Eating Disorders at Hunter College/CUNY with an affiliation to Cornell Medical Center. She completed Medical School at Ross University and did her Adult Psychiatry Training at University of Maryland/Sheppard Pratt Hospitals. Subsequently, she completed Child and Adolescent Psychiatry Fellowship Training at Johns Hopkins Hospital in Baltimore, Maryland.
  • Princeton University
  • University of Maryland Hospital
  • shepphard pratt hospita
  • Johns Hopkins School of Medicine
  • women for excellence
  • American Academy of Child & Adolescent Psychiatry
  • v
  • Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD)
  • Tourette Association of America
  • International OCD Foundation
  • ipof
  • Rotary
  • Princeton University
  • Indo American Psychiatric Association
  • Radiant Child Yoga
  • American Psychiatric Association Foundation
  • American Association of Physicians of Indian Origin (AAPI)
  • Austim After 21 Life Skills for Independent Living
  • Nordic Naturals
  • American Board of Psychiatry and Neurology, Inc.